 |
 |
|
|
|
|
|
 |
 |
 |
 |
|
 |
 |
 |
|||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
|
|
||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||
 |
 |
||||||
 |
|
||||||
 |
|
||||||
|
|
||||||
 |
 |
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
November
15th , 2005 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
"With a proven record for developing and implementing new DNA testing services, we are well equipped to deliver this important animal genotyping program for Merial," said David Hartshorne, commercial director of Orchid Cellmark's European business. "As the leading provider of scrapie genotyping services in Europe, we have successfully genotyped more than 1.7 million sheep and have developed a highly efficient and reliable laboratory service. We look forward to working with Merial so that cattle farmers can harness the power of DNA analysis in their breeding programs." Merial is a world-leading, innovation-driven animal health company providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,000 people and operates in more than 150 countries worldwide. Its 2004 sales were in excess of $1.8 billion. Its innovative IGENITY service (http://www.igenity.com) provides QTL (Qualitative Trait Loci) information about meat quality and milk production to cattle farmers. "IGENITY is entering a new growth phase and this new relationship
with Orchid Cellmark will play an important part in ensuring its success,"
said Nigel Otter, Merial's IGENITY Head for Europe. Orchid Cellmark established its European headquarters in 2001 through
the acquisition of U.K.-based Cellmark Diagnostics, among the world's
first commercial DNA testing laboratories. Under the Cellmark brand, it
is one of the largest providers of paternity and relationship testing
services in Europe, providing testing to the general public as well as
under contract to a number of government immigration departments including
the U.K. Government’s Foreign and Commonwealth Office. Orchid Cellmark
is also a leading supplier of forensic DNA profiling for criminal investigation,
a rapidly growing area in which the U.K. is a world leader. In addition,
Orchid Cellmark is a major developer and supplier of agricultural genotyping
services for genetic markers associated with disease resistance, breeding
traits and animal traceability. More information about the range of DNA
testing services and products available from Orchid Cellmark’s European
business can be found at www.orchideurope.com. IGENITY is a trademark of Merial Ltd All statements in this press release
that are not historical are forward- looking statements within the meaning
of Private Securities Litigation Reform Act of 1995, including statements
regarding: Orchid Cellmark's expectation that genotyping under the contract
with Merial will begin before the end of 2005; and Orchid Cellmark's belief
that it can work with Merial so that cattle farmers can harness the power
of DNA analysis in their breeding programs. Such statements are subject
to the risks and uncertainties that could cause actual results to differ
materially from those projected, including, but not limited to, uncertainties
relating to technologies, product development, manufacturing, market acceptance,
cost and pricing of Orchid Cellmark products and services, dependence
on government funding and collaborations, regulatory approvals, competition,
intellectual property of others, patent protection and litigation. These
risks and other additional factors affecting Orchid Cellmark's business
are discussed under the headings "Risks Related to Our Business"
and "Risks Associated with Our Common Stock" in Orchid Cellmark's
Annual Report on Form 10-K for the year ended December 31, 2004, as filed
with the Securities and Exchange Commission, and in other filings made
by Orchid Cellmark with the Securities and Exchange Commission from time
to time. Orchid Cellmark expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Orchid Cellmark's expectations
with regard thereto or any change in events, conditions, or circumstances
on which any such statements are based, except as may be required by law. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
